Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Nykode Therapeutics AS's shares outstanding for the quarter that ended in Mar. 2026 was 326.55 Mil.
Nykode Therapeutics AS's quarterly shares outstanding
stayed the same
from Dec. 2025 (326.55 Mil) to Mar. 2026 (326.55 Mil).
Nykode Therapeutics AS's annual shares outstanding
stayed the same
from Dec. 2024 (326.55 Mil) to Dec. 2025 (326.55 Mil).
Nykode Therapeutics AS (OTCPK:VACBF) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Nykode Therapeutics AS Shares Outstanding (EOP) Related Terms
Nykode Therapeutics AS Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Nykode Therapeutics AS's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nykode Therapeutics AS Shares Outstanding (EOP) Chart
VACBF vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Shares Outstanding (EOP) falls into.
Nykode Therapeutics AS Shares Outstanding (EOP) Calculation
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 326.55 Mil mean?
Nykode Therapeutics AS (VACBF) has a Shares Outstanding (EOP) of 326.55 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Shares Outstanding (EOP) too high?
Nykode Therapeutics AS's current Shares Outstanding (EOP) is 326.55 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Shares Outstanding (EOP) compare to VRTX and REGN?
Nykode Therapeutics AS's Shares Outstanding (EOP) of 326.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Shares Outstanding (EOP) is 326.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.64, compared to a current price of $0.32 — trading 49.8% below its estimated fair value. The current Shares Outstanding (EOP) is 326.55 Mil. Nykode Therapeutics AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Shares Outstanding (EOP) is 326.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of $0.32 is trading 49.8% below its estimated GF Value™ of $0.64.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for VACBF:
Shares Outstanding (EOP): 326.55 Mil
GF Value™: $0.64 vs. price of $0.32 (49.8% below fair value)
No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
28GF Score
Get the complete analysis for VACBF
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VACBF has been successfully added to your 
